Reunion Neuroscience Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a REUN research report →
Companywww.fieldtriphealth.com
Field Trip Health Ltd. engages in the development and delivery of psychedelic- assisted therapies in North America. The company operates Field Trip Health Centres that provide psychedelic therapies; offers Field Trip Digital apps; operates Field Trip Discovery, a drug development division that develops the next generation of psychedelic molecules; and provides ketamine-assisted therapy for the treatment of depression, anxiety, addiction, and other conditions.
- CEO
- Gregory T. Mayes
- IPO
- 2020
- Employees
- 16
- HQ
- Toronto, ON, CA
Price Chart
Valuation
- Market Cap
- $13.12M
- P/E
- -0.34
- P/S
- 0.00
- P/B
- 0.78
- EV/EBITDA
- 0.42
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -109.89%
- ROIC
- -82.61%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-66,220,667 · -18.70%
- EPS
- $-5.69 · -17.81%
- Op Income
- $-20,374,630
- FCF YoY
- 41.19%
Performance & Tape
- 52W High
- $21.56
- 52W Low
- $0.63
- 50D MA
- $1.02
- 200D MA
- $1.12
- Beta
- 4.20
- Avg Volume
- 429.86K
Get TickerSpark's AI analysis on REUN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our REUN Coverage
We haven't published any research on REUN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate REUN Report →